<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Thoracic <z:hpo ids='HP_0004942'>aortic aneurysms</z:hpo> (<z:chebi fb="2" ids="32497">TAAs</z:chebi>) are a potential life-threatening disease with limited pharmacological treatment options </plain></SENT>
<SENT sid="1" pm="."><plain>Current treatment options are aimed at lowering aortic hemodynamic stress, predominantly with β-adrenoceptor blockers </plain></SENT>
<SENT sid="2" pm="."><plain>Increasing evidence supports a role for the renin-angiotensin system (<z:mp ids='MP_0011356'>RAS</z:mp>) in <z:hpo ids='HP_0002617'>aneurysm</z:hpo> development </plain></SENT>
<SENT sid="3" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> blockade would not only lower blood pressure, but might also target the molecular pathways involved in <z:hpo ids='HP_0002617'>aneurysm</z:hpo> formation, in particular the transforming growth factor-β and extracellular signal-regulated kinase 1/2 pathways </plain></SENT>
<SENT sid="4" pm="."><plain>Indeed, the <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 1 (AT₁) receptor blocker <z:chebi fb="0" ids="6541">losartan</z:chebi> was effective in lowering aortic root growth in mice and patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan's syndrome</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain><z:mp ids='MP_0011356'>RAS</z:mp> inhibition (currently possible at 3 levels, i.e. renin, ACE and the AT₁ receptor) is always accompanied by a rise in renin due to interference with the negative feedback loop between renin and <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>Only during AT₁ receptor blockade will this result in stimulation of the non-blocked <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type 2 (AT₂) receptor </plain></SENT>
<SENT sid="7" pm="."><plain>This review summarizes the clinical aspects of <z:chebi fb="2" ids="32497">TAAs</z:chebi>, provides an overview of the current mouse models for <z:chebi fb="2" ids="32497">TAAs</z:chebi>, and focuses on the <z:mp ids='MP_0011356'>RAS</z:mp> as a new target for <z:chebi fb="2" ids="32497">TAA</z:chebi> treatment, discussing in particular the possibility that AT₂ receptor stimulation might be crucial in this regard </plain></SENT>
<SENT sid="8" pm="."><plain>If true, this would imply that AT₁ receptor blockers (and not <z:chebi fb="2" ids="35457">ACE inhibitors</z:chebi> or renin inhibitors) should be the preferred treatment option for <z:chebi fb="2" ids="32497">TAAs</z:chebi> </plain></SENT>
</text></document>